Breaking News Instant updates and real-time market news.

ICPT

Intercept

$98.12

-15.36 (-13.54%)

07:52
09/13/17
09/13
07:52
09/13/17
07:52

Intercept talks raise concern of potentially larger issue, says Morgan Stanley

Morgan Stanley analyst Andrew Berens noted that Intercept attended the firm's healthcare conference and discussed its recently sent "Dear Healthcare Provider" letter regarding liver toxicity seen with Ocaliva in some PBC patients. Discussion at the event suggests Ocaliva may have direct effect on liver toxicity in the presence of cholestasis and/or high drug levels, according to Berens, who sees this issue having significant implications for the drug, especially in NASH patients, he tells investors. Berens keeps an Underweight rating and $75 price target on Intercept shares, which closed yesterday down 13.5% at $98.12.

ICPT Intercept
$98.12

-15.36 (-13.54%)

09/12/17
CANT
09/12/17
NO CHANGE
Target $69
CANT
Underweight
Cantor reiterates $69 target on Intercept after Ocaliva warning letter
Cantor Fitzgerald analyst Elemer Piros reiterates an Underweight rating on Intercept Pharmaceuticals after the company sent a letter to healthcare providers warning that serious liver injuries, including death, have been reported in liver-impaired primary biliary cholangitis patients dosed with Ocaliva at higher than recommended levels. The news raises caution on the PBC franchise's future growth potential in more severe patients, and signals a "potential hurdle" for further penetration, Piros tells investors in a research note. Intercept in early trading is down 19% to $92.08.
09/12/17
JEFF
09/12/17
NO CHANGE
JEFF
Intercept selloff an 'overreaction,' says Jefferies
Jefferies analyst Michael Yee said the sell off in Intercept shares is an "overreaction" to the "Dear Healthcare Provider Letter" and said the risk/benefit of OCA remains favorable. The analyst said there is no change to his Buy thesis and $275 price target and would be buyers of the stock and expects shares to recover as the Phase III trial in cirrhotic patients is initiated by year-end and as we approach Phase III NASH results in early 2019.
09/12/17
BARD
09/12/17
NO CHANGE
Target $332
BARD
Outperform
Baird would buy Intercept on weakness
Baird analyst Brian Skorney recommends buying Intercept shares on weakness related to the "Dear Healthcare Provider Letter." The analyst said there is no new information in the letter and serves as a reminder to modify does according to the label for patients with hepatic impairment following cases of Ocaliva being dosed more frequently than recommended. Skorny rates Intercept an Outperform with a $332 price target.
09/13/17
SBSH
09/13/17
NO CHANGE
Target $150
SBSH
Buy
Intercept price target lowered to $150 from $240 at Citi
Citi analyst Joel Beatty lowered his price target for Intercept Pharmaceuticals to $150 saying a "more robust" competitive landscape in both primary biliary cholangitis and nonalcoholic steatohepatitis could limit peak sales of Ocaliva. While the drug appears to be effective and safe in NASH, its overall profile may "not be strong enough to drive a rapid increase" in the NASH diagnosis rate upon approval, limiting the drug's first mover advantage, Beatty tells investors in a research after the company sent a letter to health care providers warning that serious liver injuries, including death, have been reported in primary biliary cholangitis patients dosed with Ocaliva at higher than recommended levels. Safety concerns are likely to remain an overhang on the shares at least until results from the Phase 3 Regenerate trial in the first half of 2019, which is beyond the 12 month time horizon of the new target price, Beatty writes. He keeps a Buy rating on Intercept. The stock yesterday closed down 13.5%, or $15.36, to $98.12.

TODAY'S FREE FLY STORIES

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

05:12
09/20/17
09/20
05:12
09/20/17
05:12
Recommendations
Bed Bath & Beyond analyst commentary  »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRN

Acceleron

$38.97

-0.41 (-1.04%)

05:10
09/20/17
09/20
05:10
09/20/17
05:10
Recommendations
Acceleron analyst commentary  »

Acceleron price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

ICPT

Intercept

$96.20

0.45 (0.47%)

05:01
09/20/17
09/20
05:01
09/20/17
05:01
Recommendations
Intercept analyst commentary  »

Intercept recent pullback…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YAHOY

Yahoo Japan

$9.02

-0.03 (-0.33%)

04:57
09/20/17
09/20
04:57
09/20/17
04:57
Downgrade
Yahoo Japan rating change  »

Yahoo Japan downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$19.25

1.4 (7.84%)

04:56
09/20/17
09/20
04:56
09/20/17
04:56
Initiation
Epizyme initiated  »

Epizyme initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

CSGP

CoStar Group

$280.60

3.97 (1.44%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
CoStar Group management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

YEXT

Yext

$12.99

-0.27 (-2.04%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Yext management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

FCFS

First Cash Financial

$60.65

0.65 (1.08%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
First Cash Financial management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 22

    Sep

VNRX

VolitionRx

$2.75

0.07 (2.61%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
VolitionRx management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Citigroup to hold a conference »

2017 SMID and Travel…

SRCL

Stericycle

$70.19

-0.81 (-1.14%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Stericycle management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 27

    Sep

FIVN

Five9

$22.17

0.31 (1.42%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Five9 management to meet with Roth Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 25

    Sep

GMS

GMS Inc.

$33.50

-0.38 (-1.12%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
GMS Inc. management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

HRTG

Heritage Insurance

$11.83

-0.72 (-5.74%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Heritage Insurance management to meet with Sandler O'Neill »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

HZNP

Horizon Pharma

$12.10

0.26 (2.20%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Horizon Pharma management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

OHI

Omega Healthcare

$32.53

-0.12 (-0.37%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Omega Healthcare management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MZDAF

Mazda

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Mazda management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

SFS

Smart & Final Stores

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Smart & Final Stores management to meet with Loop Capital »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

SRCI

SRC Energy

$8.18

0.16 (2.00%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
SRC Energy management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 25

    Sep

  • 16

    May

EMR

Emerson

$63.21

0.22 (0.35%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Emerson management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

04:55
09/20/17
09/20
04:55
09/20/17
04:55
General news
Existing Home Sales to be reported at 10:00 »

August Existing Home…

SCSC

Scansource

$40.70

-0.05 (-0.12%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Scansource management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

ARLP

Alliance Resource Partners

$18.90

-0.05 (-0.26%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Alliance Resource Partners management to meet with MKM Partners »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Piper Jaffray to hold a tour »

Permian Basin BBQ &…

AITB

AIT Therapeutics

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
AIT Therapeutics management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 26

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.